Breast cyst fluid protein assay

• US 4,229,426 A
• Filed: 02/22/1978
• Issued: 10/21/1980
• Est. Priority Date: 02/22/1978
• Status: Expired due to Term

• Current Assignee: Duke University Inc (Duke University)
• Original Assignee: Duke University Inc (Duke University)
• Inventors: Haagensen, Darrow E. Jr.
• Primary Examiner(s): Padgett, Benjamin R.
• Assistant Examiner(s): Nucker, Christine M.
• Application Number:
  US05/880,257
• Time in Patent Office: 972 Days
• Field of Search: 424/1, 424/12, 23/230 B, 260/112 R
• US Class Current: 436/540
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: Y10S 436/813 Cancer
• CPC Class Codes: Y10S 530/806 Antigenic peptides or proteins
• CPC Class Codes: Y10S 530/815 Carrier is a synthetic polymer
• CPC Class Codes: Y10S 530/828 Cancer

Abstract

This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDFP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.

Claims

1. A method for determing the concentration of the glycoprotein gross cystic disease fluid protein-15 (GCDFP-15) in a biological fluid sample which method comprises conducting an immunoassay for said glycoprotein in said sample utilizing as reagents a GCDFP-15 selective antibody and GCDFP-15 labelled with a unique and detectable label to produce an antigen-antibody reaction product, separating said product from the said reagents and determining the concentration of GCDFP-15 in said sample by detecting the quantitative value of said label in either said reaction product or said reagents and comparing said label value to a standard curve wherein said GCDFP-15 is further characterized as follows:

(a) a glycoprotein having a calculated monomer size of about 15,000 daltons as determined by sodium dodecyl sulfate acrylamide gel analysis; and

(b) immunologically not identical to any components of plasma as determined by Ouchterlony analysis; and

(c) immunological cross identity with a component of human milk and human saliva.

2. The method of claim 1 wherein said immunoassay is a radioimmunoassay and said labelled GCDFP-15 is GCDFP-15 labelled with a radioactive isotope.

3. A method useful in detection of metastatic breast carcinoma disease and for monitoring the effectiveness of therapeutic regimens in patients with said metastatic disease which method comprises determining the concentration of the glycoprotein gross cystic disease fluid protein-15 (GCDFP-15) in plasma samples from said patients on at least two separate occasions by conducting an immunoassay for said glycoprotein in each said plasma sample utilizing as reagents a GCDFP-15 selective antibody and GCDFP-15 labelled with a unique and detectable label to produce an antigen-antibody reaction produce, separating said product from the said reagents and determining the concentration of GCDFP-15 in the plasma by detecting the quantitative value of said label in either said reaction product or said reagents and comparing said label value to a standard curve whereby a decrease in the level of the GCDFP-15 in serial plasma samples is indicative of disease regression or stabilization and an increase in the level of the GCDFP-15 in serial plasma samples is indicative of disease progression wherein said GCDFP-15 is further characterized as follows:

(a) a glycoprotein having a calculated monomer size of about 15,000 daltons as determined by sodium dodecyl sulfate acrylamide gel analysis; and

(b) immunologically not identical to any components of plasma as determined by Ouchterlony analysis; and

(c) immunological cross identity with a component of human milk and human saliva.

4. The method of claim 3 wherein said immunoassay is a radioimmunoassay and said labelled GCDFP-15 labelled with a radioactive isotope.

5. The method of claim 4 wherein said radioactive isotope is ¹²⁵ I.

6. The method of claim 4 wherein the antigen-antibody reaction product is precipitated, the counts of the precipitate detected and the amount of GCDFP-15 in each said plasma sample is determined from a standard inhibition curve.

7. The method of claim 4 wherein each said fluid sample is plasma.

8. The method of claim 6 wherein said antigen-antibody reaction product is precipitated with zirconyl phosphate gel.

9. The method of claim 4 wherein each said fluid sample is urine.

10. The method of claim 6 wherein said antigen-antibody reaction product is precipitated with a second antibody supported on an insoluble solid support said second antibody being immunologically reactive with the antigen-antibody reaction product.

11. The method of claim 10 wherein said antigen-antibody reaction product is precipitated with goat anti-rabbit IgG on vinylidene fluoride polymer.

12. The method of claim 3 wherein said patients are initially tested for both carcinoembryonic antigen and GCDFP-15 levels.